arrow
R

Rodney Sinclair

Sinclair Dermatology
H指数:76
被引数:2.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo

特兰基洛(Tranquillo)III期临床试验设计方案/研究方案描述,以评估利特昔替尼(Ritlecitinib)在成人及青少年非节段性白癜风患者中的应用

2026-05-220
OAAI
Clinicopathological features and treatment outcomes of fibrosing alopecia in a pattern distribution: a multicentre cohort study

纤维化斑秃在模式分布下的临床病理特征及治疗结局:一项多中心队列研究

2025-12-010
OAAI
362 Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

362 乌帕替尼在成人和青少年重度斑秃患者中的疗效、安全性和耐受性:来自随机、安慰剂对照、双盲III期研究(UP-AA)的结果

2025-11-100
PRE
Alopecia areata

斑秃

2025-11-060
PRE
Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata

新型利特昔替尼50 mg和100 mg治疗斑秃的III期、外部和合成安慰剂对照临床试验的原理与设计

2025-10-140
OA
Improvement in Patient-Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO-2b/3

斑秃患者使用Ritlecitinib治疗后,患者报告的情绪症状和因脱发导致的活动受限的改善:ALLEGRO-2b/3的附加分析

2025-10-090
OAAI
Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

更正:来自ALLEGRO临床研究项目的口服JAK3/TEC家族激酶抑制剂Ritlecitinib治疗斑秃的综合安全性分析

2025-09-110
OAAI
Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement

成人中重度斑秃的系统治疗:更新的澳大利亚专家共识声明

2025-09-011
OAAI
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

来自前额纤维性脱发国际专家联盟的声明:SOFFIA 2024

2025-07-230
OAAI
Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment

巴瑞替尼在重症斑秃成人患者中的安全性:基于两项III期临床试验,随访中位时间为2.3年,最长治疗时间达4年。

2025-04-110
OA
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme

在ALLEGRO临床开发计划中,接受利特昔替尼治疗斑秃患者的临床反应模式

2025-02-171
OAAI